Literature DB >> 25941430

Study of the effects of cyclooxygenase-2 inhibitor on the promotion of hepatic tumorigenesis in rats fed a high fat diet.

Magda Hamzawy1, Laila Elsaid1, Asmaa Shams1, Laila Rashid2, Soheir Mahfouz3, Nivin Sharawy1.   

Abstract

BACKGROUND/
OBJECTIVE: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide. The highest prevalence of hepatitis is an important risk factor contributing to development of HCCs. However, an increasing number of cases are associated metabolic disease and steatohepatitis. Inflammation associated with many liver disease, seems to be a necessary pre-requisite for successful tumor initiation. Mechanisms that link high fat diet and inflammation initial stage of HCC are not completely understood. The present work was designed to investigate the effect of fat, through modulation of the insulin-like growth factors I and II (IGF-I and IGF-II), on the promotion of hepatocellular carcinoma, and the role of cyclooxygenase 2 (COX-2).
METHODS: two main groups of rats were used: control and HCC groups. The HCC group was further sub-divide in to two subgroups, HCC fed with standard diet and HCC fed with high fat diet. The effects of celecoxib were also investigated in HCC fed with high fat diet.
RESULTS: We found that high fat diet was associated with significant increases in COX2 and interleukin 6 (IL6) with significant promotion of HCC progression. The significant increase in IGF could contribute partially to the observed effects of high fat diet. In addition, celecoxib was found to significantly reduce HCC progression.
CONCLUSIONS: We conclude that COX2 could play central role in high prevalence of HCC observed with high fat diet. Several triggering factors such as IGF and IL6, together with the direct modulation of fat metabolism could open several novel preventive strategies of celecoxib treatment, and could be useful biomarkers for assessment of its pharmacological effects.

Entities:  

Keywords:  AFP, alpha-fetoprotein; CCl4, carbon-tetrachloride; COX-2, cyclooxygenase 2; FAS, fatty acid synthase; FFA, free fatty acid; GH, growth hormone; H&E, Hematoxylin and Eosin stain; HCC, hepatocellular carcinoma; IGF; IGF-I and IGF-II, insulin-like growth factors I and II; IGFBP-3, insulin-like growth factor-binding protein 3; IGFR, IGF receptor; IL6, interleukin 6; IκB, inhibitory protein; JNK1, c-Jun N-terminal kinase-1; MAPK, mitogen-activated protein kinase; NFκB, nuclear factor-κB; PAS, periodic acid Schiff stain; PI3k, phosphatidylinositide 3-kinases; TAG, triaceyl glycerol; celecoxib; fat diet; hepatocellular carcinoma; real time-PCR, real time-polymerase chain reaction

Year:  2015        PMID: 25941430      PMCID: PMC4415194          DOI: 10.1016/j.jceh.2014.12.010

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  45 in total

Review 1.  COX and cancer.

Authors:  D Mazhar; R Gillmore; J Waxman
Journal:  QJM       Date:  2005-10

2.  IL-6 -174G/C polymorphism and IL-6 serum levels in patients with liver cirrhosis and hepatocellular carcinoma.

Authors:  Lydia Giannitrapani; Maurizio Soresi; Antonio Giacalone; Maria Elisa Campagna; Marta Marasà; Melchiorre Cervello; Salvatore Marasà; Giuseppe Montalto
Journal:  OMICS       Date:  2011-02-17

Review 3.  Nutritional regulation of the insulin-like growth factors.

Authors:  J P Thissen; J M Ketelslegers; L E Underwood
Journal:  Endocr Rev       Date:  1994-02       Impact factor: 19.871

Review 4.  The pathway from diabetes and obesity to cancer, on the route to targeted therapy.

Authors:  Emily J Gallagher; Yvonne Fierz; Rosalyn D Ferguson; Derek LeRoith
Journal:  Endocr Pract       Date:  2010 Sep-Oct       Impact factor: 3.443

Review 5.  Mechanisms of disease progression in nonalcoholic fatty liver disease.

Authors:  Janice Jou; Steve S Choi; Anna Mae Diehl
Journal:  Semin Liver Dis       Date:  2008-10-27       Impact factor: 6.115

Review 6.  Biological & physiological aspects of action of insulin-like growth factor peptide family.

Authors:  Jasminka Pavelić; Tanja Matijević; Jelena Knezević
Journal:  Indian J Med Res       Date:  2007-04       Impact factor: 2.375

7.  Celecoxib decreases fatty acid synthase expression via down-regulation of c-Jun N-terminal kinase-1.

Authors:  Suying Lu; Michael C Archer
Journal:  Exp Biol Med (Maywood)       Date:  2007-05

8.  Characterization of insulin-like-growth factor II (IGF II) mRNA positive hepatic altered foci and IGF II expression in hepatocellular carcinoma during diethylnitrosamine-induced hepatocarcinogenesis in rats.

Authors:  Biswajit Mukherjee; Shampa Ghosh; Tanushree Das; Manika Doloi
Journal:  J Carcinog       Date:  2005-08-10

9.  Development of IGF signaling antibody arrays for the identification of hepatocellular carcinoma biomarkers.

Authors:  Qi Zhou; Ying-Qing Mao; Wei-Dong Jiang; Yun-Ru Chen; Ren-Yu Huang; Xiang-Bing Zhou; Ya-Feng Wang; Zhi Shi; Zhong-Sheng Wang; Ruo-Pan Huang
Journal:  PLoS One       Date:  2012-10-11       Impact factor: 3.240

10.  Calorie restriction and cancer prevention: a mechanistic perspective.

Authors:  Stephen D Hursting; Sarah M Dunlap; Nikki A Ford; Marcie J Hursting; Laura M Lashinger
Journal:  Cancer Metab       Date:  2013-03-07
View more
  1 in total

1.  Extract of Ginkgo biloba exacerbates liver metastasis in a mouse colon cancer Xenograft model.

Authors:  Huan Wang; Xia Wu; Stephane Lezmi; Qian Li; William G Helferich; Yueqing Xu; Hong Chen
Journal:  BMC Complement Altern Med       Date:  2017-12-02       Impact factor: 3.659

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.